Pune: Glenmark Pharmaceuticals Ltd (Glenmark), a research-led, global pharmaceutical company, has launched a biosimilar of the popular 10,11 anti-diabetic drug, Liraglutide, for the first time in India.
The drug is being marketed under the brand name Lirafit following approval from the Drug Controller General of India (DCGI).
Priced at around Rs 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by
approximately 70 per cent, and will be available only under prescription.
Liraglutide has been approved globally for the management of type 2 diabetes mellitus in adult patients in the United States and the European Union, said a press release here on Wednesday.